好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson’s disease
Movement Disorders
P1 - Poster Session 1 (9:00 AM-5:00 PM)
275

To assess if soluble urokinase-type plasminogen activator receptor (SuPAR) is elevated in patients with Parkinson’s disease(PD).

SuPAR is a chronic marker of inflammation and immune activation. This inflammatory biomarker that has been shown to be associated with advanced aging1 and increased mortality in various patient groups2, 3, but has never been studied in patients with PD.

in this observational case control study, patients with varying stages of PD (early n=25, HY 1-3 n=25, and HY 4-5 n=10) and healthy controls (n=36) were recruited and underwent clinical phenotyping with assessments including SF-36, MOCA, MDS-UPDRS, HAM-D, general and neurological exam, and blood collection.  SuPAR was analyzed using Quantikine® ELISA Human SuPAR Immunoassay. For two groups comparisons, t test, rank sum test or chi-square test were used. For four groups comparisons, ANOVA, Kruskal-Wallis test or chi-square test were used.  
Healthy controls (n=36) and subjects with PD (n=60) respectively had a mean age of 63.25 (IQR 8.83 vs 65.93 years old (IQR 10.06); p=0.18), minority were women (17 (47.22%) vs 25 (41.67%); p=0.6), and majority were white (33 (91.67%) vs 60 (100.00%); p=0.05). Subjects with PD (HY4-5) had elevated SuPAR compared to healthy controls, and the highest levels were observed within patients with more advanced Parkinson’s disease (4.51 ng/mL (IQR 1.30) compared to 3.36 ng/mL, (IQR 1.03); p=0.004). However, when controlling for age as a covariate in a linear regression analysis, this difference was no longer significant.
Patient’s with PD, especially advanced PD, had elevated SuPAR, but this was driven in part by age. This study supports the utility of SuPAR as a marker for aging. Future studies with a larger sample size of advanced patients are needed to better assess if SuPAR is an independent risk factor for more advanced PD.   
Authors/Disclosures
Natalie P. Witek, MD (Rush University)
PRESENTER 		Dr. Witek has nothing to disclose.
Jessica Joyce Ms. Joyce has nothing to disclose.
Roshni A. Patel, MD (Jesse Brown VA) Dr. Patel has nothing to disclose.
No disclosure on file
No disclosure on file
Bichun Ouyang Bichum Ouyang has nothing to disclose.
No disclosure on file
No disclosure on file
Deborah H. Hall, MD, PhD, FAAN (Rush University) Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from NIH.